HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Eyelash Growth Drug Wins Over FDA Panel, Steps Closer To Approval

This article was originally published in The Rose Sheet

Executive Summary

FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted unanimously (9-0) Dec. 5 to recommend approval of Allergan's eyelash growth-stimulating drug, Latisse
Advertisement

Related Content

Jan Marini responds to Latisse
Jan Marini responds to Latisse
FDA approves Allergan eyelash enhancer
FDA approves Allergan eyelash enhancer
Jan Marini Explores Anti-Aging Hair-Care Frontier With Revamped Conditioner
Jan Marini Ceases Eyelash Product Sales Due To Allergan Suit, FDA Threat
Jan Marini Ceases Eyelash Product Sales Due To Allergan Suit, FDA Threat
Advertisement
UsernamePublicRestriction

Register

RS015845

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel